DRG Market Assessment reports

Hormone receptor (HR)-positive / HER2-negative breast cancer is the most prevalent breast cancer subtype. Targeted therapies aimed at CDK4/6 inhibition (Pfizer’s Ibrance, Novartis’s Kisqali,…

Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…

Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…

The treatment of Parkinson’s disease (PD) requires personalized care, a high degree of polypharmacy, and frequent adjustments to achieve symptom control throughout the disease course…

Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Clarivate Epidemiology’s coverage of membranous nephropathy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed prevalence and…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key MN patient populations, covering 171 countries and more than 99% of…

TNF-α inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Simponi, and UCB’s Cimzia) are approved to treat nonradiographic axial spondyloarthritis (nr-AxSpA) in Europe and are…

Clarivate Epidemiology’s coverage of primary immune thrombocytopenic purpura (ITP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…

Non-small-cell lung cancer (NSCLC)—the primary cause of cancer-related mortality in China—has a very dynamic pipeline that includes numerous targeted and biomarker-driven therapies. Notably,…

Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…